Trump's Generic Drug Tariffs Threaten U.S. Medicine Prices

Industry leaders are expressing concerns regarding Donald Trump's proposed tariffs on generic drugs, which could significantly raise medicine prices in the United States. The proposal includes a 100% duty on imported off-patent medications after two years, escalating to a 200% levy the following year.

Pharmaceutical executives warn that these tariffs cannot be absorbed internally due to the low profit margins on generic drugs, which constitute over 90% of prescriptions filled in the U.S. Major foreign suppliers, particularly from India, have indicated that relocating production to the U.S. is economically impractical.

Consequently, once the grace period ends, manufacturers will likely raise wholesale prices, directly impacting consumers' pharmacy copays and out-of-pocket expenses. While the policy aims to enhance national security by encouraging domestic manufacturing, the strategy of imposing high import taxes on generic medicines is criticized as flawed, as it disproportionately affects everyday Americans, especially those on fixed incomes.